BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LM103 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LM103\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07444437-2593@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LM103: Phase 2 readout est. (NCT07444437)
DESCRIPTION:LM103\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lu
 ng Cancer\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lm103#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444437
URL:https://assetmemo.bio/drug/lm103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310784-2593@assetmemo.bio
DTSTAMP:20261121T005601Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LM103: Phase 2 readout est. (NCT07310784)
DESCRIPTION:LM103\, phase 2.\nStudy: A Phase II Trial of LM103 in Advanced 
 Melanoma\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lm103#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07310784
URL:https://assetmemo.bio/drug/lm103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
